Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021131 | 1.00 | KCNH2 (0.44) | KCNH2SLC2A1 | |
| SCHEMBL3804841 | 0.86 | KCNH2 (0.39) | KCNH2SLC2A1 | |
| SCHEMBL3021274 | 0.76 | KCNH2 (0.46) | KCNH2 | |
| SCHEMBL3020684 | 0.76 | KCNH2 (0.46) | KCNH2 | |
| Hydrochloric Acid SCHEMBL3024007 | 0.76 | KCNH2 (0.45) | KCNH2 | |
| Hydrochloric Acid SCHEMBL3024544 | 0.76 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL3028019 | 0.74 | MCHR1 (0.35) | KCNH2 | |
| SCHEMBL15760106 | 0.73 | KCNH2 (0.50) | KCNH2SLC2A1 | |
| SCHEMBL3019036 | 0.72 | KCNH2 (0.61) | KCNH2 | |
| SCHEMBL14308959 | 0.71 | KCNH2 (0.48) | KCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| EP-2139898-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008128961-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | NRDC, MRPL21, NISCH | KCNH2 2445/4885SLC2A1 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.